The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Al...The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Although minimally invasive endoscopic hematoma evacuation is widely used to treat this disease, the technique still has room for improvement. Equipment for the intra-neuroendoscopic technique（INET） consists of two of our patented inventions： a transparent sheath（Patent No. ZL 200820046232.0） and a hematoma aspirator（Patent No. ZL 201520248717.8）. This study explored the safety and efficacy of INET by comparing it with extraventricular drainage in combination with urokinase thrombolytic therapy. This trial recruited 65 patients with severe intraventricular hemorrhage, including 35（19 men and 16 women, aged 53.2 ± 8.7 years） in the INET group and 30（17 men and 13 women, aged 51.5 ± 7.9 years） in the control group（extraventricular drainage plus urokinase thrombolytic therapy）. Our results showed that compared with the control group, the INET group exhibited lower intraventricular hemorrhage volumes, shorter intensive care-unit monitoring and ventricular drainage-tube placement times, and fewer incidences of intracranial infection, secondary bleeding, and mortality. Thus, the prognosis of survivors had improved remarkably. These findings indicate that INET is a safe and efficient new method for treating severe intraventricular hematoma. This trial was registered with Clinical Trials.gov（NCT02515903）.展开更多
Neurocytoma,a rare brain tumor,is characterized by a mass located mainly in cerebral ventricles.It is prone to be misdiagnosed as oligodendroglioma or ependymoma due to their similar histopathological features in clin...Neurocytoma,a rare brain tumor,is characterized by a mass located mainly in cerebral ventricles.It is prone to be misdiagnosed as oligodendroglioma or ependymoma due to their similar histopathological features in clinical practice.This study aimed to examine the clinicopathological features and differential diagnosis of central and extraventricular neurocytoma.The clinical and histopathological data of 17 patients (male:female=7:10;age:4-41 years;mean age:27.4 years) with central or extraventricular neurocytoma were retrospectively analyzed.These patients showed typical radiological,histopathological and immunohistochemical features of neurocytoma.The tumor tissue was found to be composed of small uniform cells with round nuclei and clear cytoplasm resembling that of oligodendroglioma and ependymoma.Immunohistochemistry revealed the tumor tissues were positive for neuronal markers such as synaptophysin (SYN) and neuronal nuclear antigen (NeuN).It was concluded histopathological features of neurocytoma overlaps with some tumors in the central neural system.Immunopositivity for SYN and NeuN can help differentially diagnose neurocytoma.展开更多
Central neurocytoma （CN）, first described by Hassoun et al in 1982, is a rare neuronal tumor of the centralnervous system, and accounts for 0.25%-0.5% of all intracranial tumors. CN commonly occurs as an intraventri...Central neurocytoma （CN）, first described by Hassoun et al in 1982, is a rare neuronal tumor of the centralnervous system, and accounts for 0.25%-0.5% of all intracranial tumors. CN commonly occurs as an intraventricular mass but may also occur as a periventricular parenchymal mass or even in locations remote from the ventricles, in which case it is termed as an extraventricular neurocytoma （EVN） （cerebral）. EVNs show a wide variability with regard to morphologic features, cellularity, and proliferation rate and are more frequently associated with poorer clinical outcomes than CNs. 1 To our knowledge, little is known regarding the treatment of atypical neurocytomas.展开更多
基金funded by a grant from the Clinical Research Project of Shenzhen Health and Family Planning Commission in China,No.SZLY2018007a grant from the Science and Technology Planning Project of Shenzhen City of China,No.JCYJ 20150403101028210+2 种基金a grant from the Science and Technology Development and Cultivation Project of Southern Medical University of China,No.KJ 20161115the Guangdong Provincial Medical Research Fund in China,No.A2016545the Shenzhen Health Planning Commission Research Fund in China,No.201601013,201506009
文摘The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Although minimally invasive endoscopic hematoma evacuation is widely used to treat this disease, the technique still has room for improvement. Equipment for the intra-neuroendoscopic technique（INET） consists of two of our patented inventions： a transparent sheath（Patent No. ZL 200820046232.0） and a hematoma aspirator（Patent No. ZL 201520248717.8）. This study explored the safety and efficacy of INET by comparing it with extraventricular drainage in combination with urokinase thrombolytic therapy. This trial recruited 65 patients with severe intraventricular hemorrhage, including 35（19 men and 16 women, aged 53.2 ± 8.7 years） in the INET group and 30（17 men and 13 women, aged 51.5 ± 7.9 years） in the control group（extraventricular drainage plus urokinase thrombolytic therapy）. Our results showed that compared with the control group, the INET group exhibited lower intraventricular hemorrhage volumes, shorter intensive care-unit monitoring and ventricular drainage-tube placement times, and fewer incidences of intracranial infection, secondary bleeding, and mortality. Thus, the prognosis of survivors had improved remarkably. These findings indicate that INET is a safe and efficient new method for treating severe intraventricular hematoma. This trial was registered with Clinical Trials.gov（NCT02515903）.
文摘Neurocytoma,a rare brain tumor,is characterized by a mass located mainly in cerebral ventricles.It is prone to be misdiagnosed as oligodendroglioma or ependymoma due to their similar histopathological features in clinical practice.This study aimed to examine the clinicopathological features and differential diagnosis of central and extraventricular neurocytoma.The clinical and histopathological data of 17 patients (male:female=7:10;age:4-41 years;mean age:27.4 years) with central or extraventricular neurocytoma were retrospectively analyzed.These patients showed typical radiological,histopathological and immunohistochemical features of neurocytoma.The tumor tissue was found to be composed of small uniform cells with round nuclei and clear cytoplasm resembling that of oligodendroglioma and ependymoma.Immunohistochemistry revealed the tumor tissues were positive for neuronal markers such as synaptophysin (SYN) and neuronal nuclear antigen (NeuN).It was concluded histopathological features of neurocytoma overlaps with some tumors in the central neural system.Immunopositivity for SYN and NeuN can help differentially diagnose neurocytoma.
文摘Central neurocytoma （CN）, first described by Hassoun et al in 1982, is a rare neuronal tumor of the centralnervous system, and accounts for 0.25%-0.5% of all intracranial tumors. CN commonly occurs as an intraventricular mass but may also occur as a periventricular parenchymal mass or even in locations remote from the ventricles, in which case it is termed as an extraventricular neurocytoma （EVN） （cerebral）. EVNs show a wide variability with regard to morphologic features, cellularity, and proliferation rate and are more frequently associated with poorer clinical outcomes than CNs. 1 To our knowledge, little is known regarding the treatment of atypical neurocytomas.
